Medical treatment guidelines for preventive treatment of migraine

Tzu Chou Huang; Tzu Hsien Lai; Shuu Jiun Wang; Po Jen Wang; Yen Feng Wang; Lien Huei Lee; Kao Chang Lin; Zin An Wu; Ching Sen Shih; Yung Chu Hsu; Yen Yu Chen; Wei Hung Chen; Wei Ta Chen; Ping Kun Chen; Tzu Chou Huang; Jong Ling Fu; Chun Pai Yang; Tu Hsueh Yeh; Yi Chu Liao; Tzu Hsien Lai; Jing Jane Tsai; Shiang Ru Lu; Treatment Guideline Subcommittee of Taiwan Headache Society

Medical treatment guidelines for preventive treatment of migraine

Tzu Chou Huang, Tzu Hsien Lai, Shuu Jiun Wang, Po Jen Wang, Yen Feng Wang, Lien Huei Lee, Kao Chang Lin, Zin An Wu, Ching Sen Shih, Yung Chu Hsu, Yen Yu Chen, Wei Hung Chen, Wei Ta Chen, Ping Kun Chen, Tzu Chou Huang, Jong Ling Fu, Chun Pai Yang, Tu Hsueh Yeh, Yi Chu Liao, Tzu Hsien LaiJing Jane Tsai, Shiang Ru Lu, Treatment Guideline Subcommittee of Taiwan Headache Society

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the “start low and go slow” doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.

Original language	English
Pages (from-to)	33-35
Number of pages	3
Journal	Acta Neurologica Taiwanica
Volume	26
Issue number	1
Publication status	Published - Jan 1 2017

Keywords

Chronic migraine
Evidence-based medicine
Migraine preventive treatment
Treatment guidelines

ASJC Scopus subject areas

Neurology
Clinical Neurology

Cite this

Huang, T. C., Lai, T. H., Wang, S. J., Wang, P. J., Wang, Y. F., Lee, L. H., Lin, K. C., Wu, Z. A., Shih, C. S., Hsu, Y. C., Chen, Y. Y., Chen, W. H., Chen, W. T., Chen, P. K., Huang, T. C., Fu, J. L., Yang, C. P., Yeh, T. H., Liao, Y. C., ... Treatment Guideline Subcommittee of Taiwan Headache Society (2017). Medical treatment guidelines for preventive treatment of migraine. Acta Neurologica Taiwanica, 26(1), 33-35.

Huang, TC, Lai, TH, Wang, SJ, Wang, PJ, Wang, YF, Lee, LH, Lin, KC, Wu, ZA, Shih, CS, Hsu, YC, Chen, YY, Chen, WH, Chen, WT, Chen, PK, Huang, TC, Fu, JL, Yang, CP, Yeh, TH, Liao, YC, Lai, TH, Tsai, JJ, Lu, SR & Treatment Guideline Subcommittee of Taiwan Headache Society 2017, 'Medical treatment guidelines for preventive treatment of migraine', Acta Neurologica Taiwanica, vol. 26, no. 1, pp. 33-35.

@article{440adbee80844892a5a53dc2fdb2bdd9,

title = "Medical treatment guidelines for preventive treatment of migraine",

abstract = "The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into {\ss}-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the “start low and go slow” doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.",

keywords = "Chronic migraine, Evidence-based medicine, Migraine preventive treatment, Treatment guidelines",

author = "Huang, {Tzu Chou} and Lai, {Tzu Hsien} and Wang, {Shuu Jiun} and Wang, {Po Jen} and Wang, {Yen Feng} and Lee, {Lien Huei} and Lin, {Kao Chang} and Wu, {Zin An} and Shih, {Ching Sen} and Hsu, {Yung Chu} and Chen, {Yen Yu} and Chen, {Wei Hung} and Chen, {Wei Ta} and Chen, {Ping Kun} and Huang, {Tzu Chou} and Fu, {Jong Ling} and Yang, {Chun Pai} and Yeh, {Tu Hsueh} and Liao, {Yi Chu} and Lai, {Tzu Hsien} and Tsai, {Jing Jane} and Lu, {Shiang Ru} and {Treatment Guideline Subcommittee of Taiwan Headache Society}",

year = "2017",

month = jan,

day = "1",

language = "English",

volume = "26",

pages = "33--35",

journal = "Acta Neurologica Taiwanica",

issn = "1028-768X",

publisher = "Taiwan Neurological Society",

number = "1",

}

TY - JOUR

T1 - Medical treatment guidelines for preventive treatment of migraine

AU - Huang, Tzu Chou

AU - Lai, Tzu Hsien

AU - Wang, Shuu Jiun

AU - Wang, Po Jen

AU - Wang, Yen Feng

AU - Lee, Lien Huei

AU - Lin, Kao Chang

AU - Wu, Zin An

AU - Shih, Ching Sen

AU - Hsu, Yung Chu

AU - Chen, Yen Yu

AU - Chen, Wei Hung

AU - Chen, Wei Ta

AU - Chen, Ping Kun

AU - Huang, Tzu Chou

AU - Fu, Jong Ling

AU - Yang, Chun Pai

AU - Yeh, Tu Hsueh

AU - Liao, Yi Chu

AU - Lai, Tzu Hsien

AU - Tsai, Jing Jane

AU - Lu, Shiang Ru

AU - Treatment Guideline Subcommittee of Taiwan Headache Society

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the “start low and go slow” doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.

AB - The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects. This guideline is updated from earlier version published in 2008. Migraine preventive medications currently available in Taiwan can be categorized into ß-blockers, antidepressants, calcium channel blockers, anticonvulsants, nonsteroid anti-inflammatory drugs, OnabotulinumtoxinA and miscellaneous medications. Propranolol has the best level of evidence and fewer side-effects, and is recommended as the first-line medication for episodic migraine prevention. Valproic acid, topiramate, flunarizine and amitriptyline are suggested as the second-line medications. The rest medications are used when the above medications fail. OnabotulinumtoxinA and topiramate are recommended for chronic migraine prevention. Those other medications used for episodic migraine could also be used as a second-line option. It is not recommended to use migraine preventive medication during pregnancy or lactation. For those women with menstrual migraine, nonsteroid anti-inflammatory drugs and triptans can be used for prevention during the menstrual period. The levels of evidences for migraine preventive medications in children/adolescents and elderly are low. The preventive medications should follow the “start low and go slow” doctrine to reach an effective dosage. This can prevent adverse events and improve tolerance. The efficacy of preventive medications cannot be evaluated until 3 to 4 weeks after treatment. If the improvement of migraine maintains for 6 months, physicians can gradually taper the medications. Physicians should notify the patients not to overuse acute medications during migraine prevention treatment.

KW - Chronic migraine

KW - Evidence-based medicine

KW - Migraine preventive treatment

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=85023623066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023623066&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85023623066

SN - 1028-768X

VL - 26

SP - 33

EP - 35

JO - Acta Neurologica Taiwanica

JF - Acta Neurologica Taiwanica

IS - 1

ER -

Medical treatment guidelines for preventive treatment of migraine

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this